treace.com - TMCI Company Value to Revenue Ratio

Public company logo of Treace Medical Concepts, Inc. (TMCI)

Treace Medical Concepts (TMCI) is betting on aggressive marketing and high sales force motivation. The company's EV/Sales valuation clearly demonstrates the multiple's dynamics, where the 1572.95 level indicates the parameter's status. In-house manufacturing plants in the US and patent protection guarantee technological stability, while steady demand for Lapiplasty systems ensures a predictable cash flow.

TMCI Treace Medical Concepts: EV/Sales Multiple in the range 11/23/2025 - 11/20/2026

TMCI (Treace Medical): analytical breakdowns and indicator data

Fundamental valuation:Treace Medical Concepts TMCI
Mass-produced product of Treace Medical Concepts Inc

Investors assess fundamental capital risks by comparing the market value of the business with its operational efficiency. The monopoly position of Treace Medical Concepts (TMCI) in 3D foot implantation and the protection of its niche via the FDA create high added value for every sale. The EV/Sales multiple reflects the ratio of enterprise value, including debt, to revenue, excluding the impact of leverage. The dynamics of this metric demonstrate the premium the market is willing to pay for the unique Lapiplasty ecosystem. Steady growth in this metric confirms the company's expansion, while a prolonged decline signals a loss of investment attractiveness.

Competitor analysis for Treace Medical Concepts

BSX (Boston Scientific) - Company Value to Revenue Ratio|EW: EV/Sales Multiple|RMD - Total Company Value-to-Revenue Ratio|PODD (Insulet Inc.) - EV/Sales Multiple|Company Value to Revenue Zimmer Biomet Corp (ZBH)|EV/Sales Multiple COO|Company Value to Revenue Align Technology, Inc. ALGN|EV/Sales Multiple GMED (globusmedical.com)|EV/Sales Multiple TransMedics Group, Inc. TMDX|ATEC - Enterprise Value-to-Revenue Ratio|AORT: Enterprise Value-to-Revenue Ratio|ENOV (Enovis Corporation) - Company Value to Revenue|Integra LifeSciences - Business Value to Revenue|ESTA (Establishment Labs Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Beta Bionics, Inc. BBNX|Enterprise Value-to-Revenue Ratio IRADIMED Corp (IRMD)|Embecta Corp. (EMBC) - Enterprise Value-to-Sales Ratio|Tandem Corp - Company Value to Revenue|EV/Sales Multiple AxoGen, Inc. AXGN|SI-BONE Inc - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Orthofix Medical OFIX|Bioventus Global (BVS) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume KIDS (OrthoPediatrics Inc.)|Enterprise Value-to-Revenue Ratio blade.com|Company Value to Revenue Carlsmed Inc (CARL)|EV/Sales Multiple RXST|CLPT - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio Stereotaxis, Inc. STXS|STIM: Company Value to Revenue Ratio|SGHT: Company Value to Revenue|Orchestra BioMed Inc. - Enterprise Value-to-Revenue Coefficient|ANIK: EV/Sales Multiple|NSPR - Total Company Value-to-Revenue Ratio|ZJYL (Jin Medical) - EV/Sales Multiple|Vivani Medical (VANI) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple XTNT|EV/Sales Multiple n1mtc.com (NMTC)|Modular Medical Inc - Company Value to Revenue|Myomo, Inc (MYO) - Enterprise Value-to-Revenue Multiple|COCH: Company Value to Revenue|Total Company Value-to-Revenue Ratio Vivos Therapeutics VVOS|enVVeno Medical Corp. (NVNO) - Enterprise Value-to-Revenue Ratio|Sintx Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Tenon Medical Inc.|LFWD: Business Value to Revenue|EV/Sales Multiple AMIX|Enterprise Value-to-Revenue Coefficient IVF|Enterprise Value-to-Revenue Ratio Bone Biologics BBLG|Total Company Value-to-Revenue Ratio axonics.com (AXNX)|BIOL - Enterprise Value-to-Revenue Ratio|Dynatronics (DYNT) - Company Value to Revenue|Paragon 28, Inc. (FNA) - Enterprise Value-to-Revenue Ratio|INVO - Total Company Value-to-Revenue Ratio